The most prominent irreversible cutaneous adverse effect of extended GCs topical application is skin atrophy, which involves both the epidermis and dermis and is associated with the impairment of the skin barrier through inhibition of lipid synthesis and changes in extracellular matrix (ECM) proteins [15,17,18,19,21,39,40]. Here, PROS1 is linked to skin atrophy.